SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease hav

SEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report)'s stock had its "buy" rating reiterat

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maint

SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) has received an average recomme

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other

Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several sma

Perspective Therapeutics Inc. (NYSE:CATX) could benefit from growing interest in radiopharmaceutical

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radio

William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Comp

SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Comp

Perspective Therapeutics remains a “Strong Buy,” driven by durable clinical data and multiple near-t

BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) wit

B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Ne

Dimensional Fund Advisors LP raised its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CAT

Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.22) per share which beat the a

Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared t

Medical sector earnings are off to a strong start, and four biotech companies are positioned to pote

Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERI

SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Com

After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics

Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CAT

ADAR1 Capital Management LLC boosted its position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CA

 The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP)

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-m